Final data of the effects of the Neuro Emotional Technique (NET) for pediatric Attention-Deficit/Hyperactivity Disorder (AD/HD): A randomized controlled trial
Karpouzis, F., Bonello, R. and Pollard, H. (2011) Final data of the effects of the Neuro Emotional Technique (NET) for pediatric Attention-Deficit/Hyperactivity Disorder (AD/HD): A randomized controlled trial. Clinical Chiropractic, 14 (4). p. 144.
*Subscription may be required
Introduction: The literature reveals that two treatments have been validated as effective treatment modalities for pediatric AD/HD: psychosocial treatments, pharmacological treatments and their combination. However, controversy exists over the efficacy and safety of pharmacological therapies. As a result of this controversy, parents have been seeking complementary and alternative medicine (CAM) such as chiropractic for their children with AD/HD. The objective of this study was to determine whether the addition of the emotional component of NET therapy to an existing treatment program could improve clinical outcomes (i.e. reduce inattention, hyperactivity and impulsivity) in pediatric AD/HD. The purpose of this study was to test anecdotal claims of treatment success made by chiropractors using NET therapy for pediatric AD/HD.
Methods: An approved clinical trial was conducted in four private clinics in Sydney, Australia. Children aged 5–12 years who met inclusion criteria were randomised into three groups: Group A (Sham n = 37), Group B (NET therapy n = 59) and Group C (Control n = 32). All groups continued with their existing treatment regimens (i.e. pharmacological and/or psychosocial). Groups A and B had sham and NET protocols added respectively to existing regimens. Psychometric outcome measures were chosen from the Conners’ Rating Scales (CRS), which were scored and interpreted by independent registered clinical psychologists. The psychologists, participants, parents and teachers of groups A and B were all blinded to group allocation.
An analysis of covariance was conducted comparing the changes between baseline and final results (i.e. after seven months and 14 interventions) between the active group (NET) and placebo group (sham).
Results: Forty-one participants (10 sham; 21 NET; 10 Control) completed the protocol. CRS classified changes of five or more subscale points as significant and thus -5 was chosen as the minimally clinically important difference (MCID). Decreases in global and behavioral indices were indicative of improvements in participants’ behaviors and were considered clinically meaningful results. At the conclusion of the study, only NET therapy group achieved the MCID (>−5). The intention to treat analysis revealed that NET therapy produced significant results for all primary and secondary outcomes: Conners ADHD Index (p = 0.000, CI: −13.03, −3.96); Conners Global Index (p = 0.006, CI: −13.70, −2.46); DSM-IV:Inattentive (p = 0.031, CI: −9.94, −0.49); DSM-IV:Hyperactive/Impulsive (p = 0.003, CI: −13.91, −2.98) and DSM-IV:Total (p = 0.006, CI: −12.75, −2.23). The Cohen's d coefficient revealed medium to high effect sizes (1.08, 0.82, 0.64, 0.89 and 0.82, respectively). These significant results denote improvements in global and behavioral indices (i.e. reductions in inattention, hyperactivity and impulsivity) in participants who received NET therapy.
Conclusions: These results provide the first data towards answering the question: Does NET have a potential role to play in the management of pediatric AD/HD? This study has demonstrated clinically meaningful changes and significant results for the emotional component of NET therapy for pediatric AD/HD. Definitive recommendations cannot be made about the intervention at this time until a protocol using the whole spectrum of NET is undertaken.
|Publication Type:||Journal Article|
|Copyright:||© 2011 Published by Elsevier B.V.|
|Item Control Page|